Hansa Biopharma AB Corporate Analyst Meeting Transcript
()-
Good afternoon, and welcome to the Hansa Biopharma Capital Markets Day. My name is Klaus Sindahl, and I'm Head of Investor Relations at Hansa Biopharma. I'm very pleased that Hansa Biopharma is hosting its third Capital Markets Day here in Copenhagen on the back of an eventful summer with many milestones achieved, milestones which essentially are transforming the company into a commercial stage biopharmaceutical company.
I'm also really excited about the program and the lineup of speakers we have this afternoon. The presentations will take us through very interesting aspects of Hansa Biopharma, both in terms of our recent progress, but also highlight opportunities outside of kidney transplantation in new areas such as gene therapy and autoimmunity. This also underpins that we have a very unique technology asset with very broad commercial opportunities also outside kidney transplantation.
I also wanted to introduce today's moderator, Rachel Curtis Gravesen. Many of you would know Rachel from a long
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |